Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1454870

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1454870

Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 152 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

Global biological drugs market is on a trajectory of robust growth, with projections indicating a commendable CAGR of over 10% during the forecast period, aiming to reach a market value of US$ 800 Billion by 2031.

Unlocking New Horizons in Healthcare: The Rise of Biological Drugs

Biological drugs, derived from living cells, stand at the forefront of biomedical innovation, offering new hope for patients grappling with chronic and life-threatening illnesses. Unlike conventional medications, the complex structure of biological drugs offers targeted therapy, minimizing side effects while maximizing efficacy. This has led to a paradigm shift in the treatment and prevention strategies for numerous diseases, with governments worldwide recognizing and endorsing their use.

Market Dynamics: A Closer Look

The escalating prevalence of chronic diseases, coupled with a growing geriatric population, is propelling the demand for biological drugs. The market is also benefiting from heightened healthcare awareness initiatives by public and private organizations alike. Furthermore, advancements in biomedical technology and ongoing R&D activities are expected to expand the market's horizon even further.

However, the journey is not devoid of challenges. Patent expirations of blockbuster drugs, the high cost of biological drugs, and potential severe side effects, especially from injectable forms, are some hurdles that could temper market growth.

Segment Insights: Therapeutic Proteins Lead the Way

The global biological drugs market is segmented into therapeutic proteins, monoclonal antibodies, vaccines, and by region. Therapeutic proteins, with Enbrel at the helm, are anticipated to dominate and grow at the fastest rate during the forecast period. Monoclonal antibodies, with Humira leading the pack, are also expected to see significant growth. Among vaccines, Prevnar 13 is poised for higher demand through 2031.

Geographical Analysis: North America at the Forefront

North America is anticipated to sustain its position as the leading market for biological drugs, propelled by the growing necessity for these medications in addressing diseases such as diabetes and cancer. The region is poised to experience substantial growth, with Europe's demand largely shaped by its aging population. Meanwhile, Asia Pacific is witnessing a surge in demand due to supportive government initiatives and cost-effective manufacturing, which are attracting foreign companies.

Leading the Charge: Key Market Players

The global biological drugs market is marked by the presence of key industry players such as Merck & Co., Inc., Abbott Laboratories, Eli Lilly and Company, Baxter International Inc., Novartis AG, Pfizer Inc., Biogen Idec, Bristol-Myers Squibb Company, Amgen Inc., and GlaxoSmithKline plc. These companies are at the forefront of innovation, driving the market towards a future where biological drugs are a cornerstone of medical treatment across the globe.

Market Segmentation:

By Therapeutic Protein

  • Enbrel
  • Lantus
  • Neulasta
  • Avonex
  • NovoLog
  • Rebif
  • Humalog
  • Aranesp
  • Epogen
  • Levemir
  • Victoza
  • Betaseron
  • Neupogen
  • Eylea

By mAb

  • Humira
  • Remicade
  • Rituxan
  • Avastin
  • Herceptin
  • Lucentis

By Vaccine

  • Prenvar 13
  • Gardasil
  • Fluzone
  • Varivax
  • Cervarix

By Geography

  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Biological Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Biological Drugs Market Outlook, 2018 - 2031

  • 3.1. Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Enbrel
      • 3.1.1.2. Lantus
      • 3.1.1.3. Neulasta
      • 3.1.1.4. Avonex
      • 3.1.1.5. NovoLog
      • 3.1.1.6. Rebif
      • 3.1.1.7. Humalog
      • 3.1.1.8. Aranesp
      • 3.1.1.9. Epogen
      • 3.1.1.10. Levemir
      • 3.1.1.11. Victoza
      • 3.1.1.12. Betaseron
      • 3.1.1.13. Neupogen
      • 3.1.1.14. Eylea
  • 3.2. Global Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Humira
      • 3.2.1.2. Remicade
      • 3.2.1.3. Rituxan
      • 3.2.1.4. Avastin
      • 3.2.1.5. Herceptin
      • 3.2.1.6. Lucentis
  • 3.3. Global Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Prenvar
      • 3.3.1.2. Gardasil
      • 3.3.1.3. Fluzone
      • 3.3.1.4. Varivax
      • 3.3.1.5. Cervarix
  • 3.4. Global Biological Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Global Biological Drugs Market Outlook, 2018 - 2031

  • 4.1. North America Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Enbrel
      • 4.1.1.2. Lantus
      • 4.1.1.3. Neulasta
      • 4.1.1.4. Avonex
      • 4.1.1.5. NovoLog
      • 4.1.1.6. Rebif
      • 4.1.1.7. Humalog
      • 4.1.1.8. Aranesp
      • 4.1.1.9. Epogen
      • 4.1.1.10. Levemir
      • 4.1.1.11. Victoza
      • 4.1.1.12. Betaseron
      • 4.1.1.13. Neupogen
      • 4.1.1.14. Eylea
  • 4.2. Global Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Humira
      • 4.2.1.2. Remicade
      • 4.2.1.3. Rituxan
      • 4.2.1.4. Avastin
      • 4.2.1.5. Herceptin
      • 4.2.1.6. Lucentis
  • 4.3. Global Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Prenvar
      • 4.3.1.2. Gardasil
      • 4.3.1.3. Fluzone
      • 4.3.1.4. Varivax
      • 4.3.1.5. Cervarix
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
    • 4.4.2. Key Highlights
      • 4.4.2.1. Enbrel
      • 4.4.2.2. Lantus
      • 4.4.2.3. Neulasta
      • 4.4.2.4. Avonex
      • 4.4.2.5. NovoLog
      • 4.4.2.6. Rebif
      • 4.4.2.7. Humalog
      • 4.4.2.8. Aranesp
      • 4.4.2.9. Epogen
      • 4.4.2.10. Levemir
      • 4.4.2.11. Victoza
      • 4.4.2.12. Betaseron
      • 4.4.2.13. Neupogen
      • 4.4.2.14. Eylea
  • 4.5. North America Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. Humira
      • 4.5.1.2. Remicade
      • 4.5.1.3. Rituxan
      • 4.5.1.4. Avastin
      • 4.5.1.5. Herceptin
      • 4.5.1.6. Lucentis
  • 4.6. North America Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 4.6.1. Key Highlights
      • 4.6.1.1. Prenvar
      • 4.6.1.2. Gardasil
      • 4.6.1.3. Fluzone
      • 4.6.1.4. Varivax
      • 4.6.1.5. Cervarix
  • 4.7. North America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
      • 4.7.1.1. Key Highlights
      • 4.7.1.2. U.S. Global Biological Drugs Market by Therapeutic Protein, Value (US$Bn), 2018 - 2031
      • 4.7.1.3. U.S. Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 4.7.1.4. U.S. Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 4.7.1.5. Canada Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 4.7.1.6. Canada Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 4.7.1.7. Canada Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
    • 4.7.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Global Biological Drugs Market Outlook, 2018 - 2031

  • 5.1. Europe Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Enbrel
      • 5.1.1.2. Lantus
      • 5.1.1.3. Neulasta
      • 5.1.1.4. Avonex
      • 5.1.1.5. NovoLog
      • 5.1.1.6. Rebif
      • 5.1.1.7. Humalog
      • 5.1.1.8. Aranesp
      • 5.1.1.9. Epogen
      • 5.1.1.10. Levemir
      • 5.1.1.11. Victoza
      • 5.1.1.12. Betaseron
      • 5.1.1.13. Neupogen
      • 5.1.1.14. Eylea
  • 5.2. Europe Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Humira
      • 5.2.1.2. Remicade
      • 5.2.1.3. Rituxan
      • 5.2.1.4. Avastin
      • 5.2.1.5. Herceptin
      • 5.2.1.6. Lucentis
  • 5.3. Europe Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Prenvar
      • 5.3.1.2. Gardasil
      • 5.3.1.3. Fluzone
      • 5.3.1.4. Varivax
      • 5.3.1.5. Cervarix
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Global Biological Drugs Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Enbrel
      • 6.1.1.2. Lantus
      • 6.1.1.3. Neulasta
      • 6.1.1.4. Avonex
      • 6.1.1.5. NovoLog
      • 6.1.1.6. Rebif
      • 6.1.1.7. Humalog
      • 6.1.1.8. Aranesp
      • 6.1.1.9. Epogen
      • 6.1.1.10. Levemir
      • 6.1.1.11. Victoza
      • 6.1.1.12. Betaseron
      • 6.1.1.13. Neupogen
      • 6.1.1.14. Eylea
  • 6.2. Asia Pacific Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Humira
      • 6.2.1.2. Remicade
      • 6.2.1.3. Rituxan
      • 6.2.1.4. Avastin
      • 6.2.1.5. Herceptin
      • 6.2.1.6. Lucentis
  • 6.3. Asia Pacific Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Prenvar
      • 6.3.1.2. Gardasil
      • 6.3.1.3. Fluzone
      • 6.3.1.4. Varivax
      • 6.3.1.5. Cervarix
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Global Biological Drugs Market Outlook, 2018 - 2031

  • 7.1. Latin America Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Enbrel
      • 7.1.1.2. Lantus
      • 7.1.1.3. Neulasta
      • 7.1.1.4. Avonex
      • 7.1.1.5. NovoLog
      • 7.1.1.6. Rebif
      • 7.1.1.7. Humalog
      • 7.1.1.8. Aranesp
      • 7.1.1.9. Epogen
      • 7.1.1.10. Levemir
      • 7.1.1.11. Victoza
      • 7.1.1.12. Betaseron
      • 7.1.1.13. Neupogen
      • 7.1.1.14. Eylea
  • 7.2. Latin America Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Humira
      • 7.2.1.2. Remicade
      • 7.2.1.3. Rituxan
      • 7.2.1.4. Avastin
      • 7.2.1.5. Herceptin
      • 7.2.1.6. Lucentis
  • 7.3. Latin America Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Prenvar
      • 7.3.1.2. Gardasil
      • 7.3.1.3. Fluzone
      • 7.3.1.4. Varivax
      • 7.3.1.5. Cervarix
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Global Biological Drugs Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Enbrel
      • 8.1.1.2. Lantus
      • 8.1.1.3. Neulasta
      • 8.1.1.4. Avonex
      • 8.1.1.5. NovoLog
      • 8.1.1.6. Rebif
      • 8.1.1.7. Humalog
      • 8.1.1.8. Aranesp
      • 8.1.1.9. Epogen
      • 8.1.1.10. Levemir
      • 8.1.1.11. Victoza
      • 8.1.1.12. Betaseron
      • 8.1.1.13. Neupogen
      • 8.1.1.14. Eylea
  • 8.2. Middle East & Africa Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Humira
      • 8.2.1.2. Remicade
      • 8.2.1.3. Rituxan
      • 8.2.1.4. Avastin
      • 8.2.1.5. Herceptin
      • 8.2.1.6. Lucentis
  • 8.3. Middle East & Africa Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Prenvar
      • 8.3.1.2. Gardasil
      • 8.3.1.3. Fluzone
      • 8.3.1.4. Varivax
      • 8.3.1.5. Cervarix
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Vaccines vs by mAb Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Abbott Laboratories
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. GlaxoSmithKline plc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bristol-Myers Squibb Company
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Merck & Co., Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Amgen Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Baxter International Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Biogen Idec
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!